Pluripotential mechanisms of cardioprotection with hmg-coa reductase inhibitor therapy

American Journal of Cardiovascular Drugs

Volumn 1, Issue 6, 2001, Pages 411-420

  Rosenson, Robert S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN;

ANIMAL; BLOOD; CELL ADHESION; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; DRUG EFFECT; HEART INFARCTION; HUMAN; HYPERLIPOPROTEINEMIA; IMMUNOLOGY; INFLAMMATION; INTIMA; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RECURRENT DISEASE; REVIEW; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM;

ANGINA, UNSTABLE; ANIMALS; CELL ADHESION; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIAS; INFLAMMATION; LIPOPROTEINS; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; OXIDATIVE STRESS; RECURRENCE; TUNICA INTIMA;

EID: 0000339230     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101060-00001     Document Type: Article

References (90)

1. Downs JR, Clearfield M, Wies S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
2. Shepherd J, Cobb SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 355: 1001-9
4. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
5. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995; 345: 1274-5
6. Rosenson RS. Basic Mechanisms of stroke prevention with lipid-lowering therapy. Curr Atheroscler Rep 2000; 2: 120-5
7. Rosenson RS. Biological basis for statin therapy in stroke prevention. Curr Opin Neurol 2000; 13: 57-62
8. Rosenson RS. Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50
9. Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet 1996; 347: 305-7
10. Delanty N, Vaughan CJ. Vascular effects of statins in stroke. Stroke 1997; 28: 2315-20
11. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119: 969-76
12. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMGCoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-68
13. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-8
14. Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133-9
15. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40
16. Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278-86
17. Gotto Jr AM. Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting. Circulation 1995; 92: 646-56
18. Rosenson RS, Shalaurova I, Otvos J. Relations of lipoprotein subclass levels and LDL size to reduction in coronary atherosclerosis in the PLAC-I trial [abstract]. Atherosclerosis 2000; 151: 237
19. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5
20. Gotto Jr AM, Whitney E, Stein EA, et al. Relation between baseline and ontreatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101: 477-84
21. Friedwald WT, Levy RI, Frederickson DS. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
22. Casey PJ. Protein lipidation in cell signaling. Science 1995; 268: 221-5
23. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35
24. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl- CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998; 95: 8880-5
25. Essig M, Nguyen G, Prie D, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res 1998; 83: 683-90
26. Laufs U, Marra D, Node K, et al. 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kipl). J Biol Chem 1999; 274: 21926-31
27. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490-500
28. Sacks FM, Tonkin AM, Shepherd J, et al. Effects of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893-900
29. Stein JH, Rosenson RS. Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997; 157: 1170-6
30. Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial Effects of Pravastatin (+/- Colestyramine/Nicain) Initiated Immediately After a Coronary Event (The Randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000; 86: 1293-8
31. Schwartz GG, Olsson AG, Ezekowitz MD, et al. The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study. JAMA 2001; 285: 1711-8
32. Horne BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36: 1774-80
33. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-6
34. Rosenson RS. Statin therapy in acute cardiovascular syndromes: a new horizon. Cardiol Rev 1999 May; 1-6
35. Koudy-Williams J, Sukhova GK, Herrington DM, et al. Pravastatin has cholesterol lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998; 31: 684-91
36. Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001; 21: 115-21
37. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 2001; 103: 993-9
38. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26
39. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-4
40. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7
41. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-93
42. Aengevaeren WRM, Uijen GJH, Jukema JW, et al. Functional evaluation of lipidlowering therapy by pravastatin in the Regression Growth Evaluation Statin Study. Circulation 1997; 96: 429-35
43. Eichstadt HW, Eskotter H, Hoffmann I, et al. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: A122-5
44. van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996; 94: 1503-5
45. Andrews TC, Raby K, Barry J, et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-8
46. Dupuis J,Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-3
47. Vita JA, Yeung AC, Winniford M, et al. Effect of Cholesterol-Lowering Therapy on Coronary Endothelial Vasomotor Function in Patients With Coronary Artery Disease. Circulation 2000; 102: 846-51
48. Cannon RO. Cardiovascular Benefit of Cholesterol-Lowering Therapy: Does Improved Endothelial Vasodilator Function Matter? Circulation 2000; 102: 820-2
49. Kaesemeyer WH, Caldwell RB, Huang J, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-41
50. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. A randomized, placebo-controlled, double-blind study. Circulation 1998; 98: 211-6
51. Wilson SH, Simari RD, Best PJM, et al. Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001; 21: 122-8
52. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3- hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9
53. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999; 34: 1281-6
54. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549-5
55. Kunsch C, Medford R. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999; 85: 753-66
56. Collins T, Cybulsky MI. NF-êB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107: 255-64
57. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336: 1066-71
58. Diaz MN, Frei B, Vita JA, et al. Mechanisms of disease: antioxidants and atherosclerotic heart disease. N Engl J Med 1998; 337: 408-16
59. Tormey VJ, Faul J, Leonard C, et al. T-cell cytokines may control the balance of functionally distinct macro-phage populations. Immunology 1997; 90: 463-9
60. Hansson GK, Jonasson L, Seifert PS, et al. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989; 9: 567-78
61. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402
62. Sadeghi MM, Collinge M, Pardi R, et al. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. Immunology 2000; 165: 2712-8
63. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001; 103: 276-83
64. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998; 32: 2057-64
65. Ortego M, Bustos C, Hernández-Presa MA, et al. Atorvastatin reduces NF-êB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147 (2): 253-61
66. Weber C, Erl W, Weber KSC, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-7
67. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-33
68. Libby P, Sukhova G, Lee RT, et al. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25 Suppl. 2: S9-12
69. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1998; 353: 983-4
70. Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36: 427-31
71. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000; 101: 1760-3
72. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-44
73. Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on c-reactive protein in patients with coronary artery disease. Lancet 1999; 353: 118-9
74. Ridker PM, Rifai N, Lowenthal SP, et al. Rapid reduction in c-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-3
75. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001; 103: 1933-5
76. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP- 9 secretion by macrophages. Aterioscler Thromb Vasc Biol 1998; 18: 1671-8
77. Rosenson RS, Lowe GDO. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140: 271-80
78. Colli S, Eligini S, Lalli M, et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997; 17: 265-72
79. Lawson JH, Butenas S, Mann KG. The evaluation of complex dependent alterations in human factor VIIa. J Biol Chem 1992; 267: 4834-3
80. Carvalho AC, Colman RW, Less RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-8
81. Corash L, Andersen J, Poindexter BJ, et al. Platelet function and survival in patients with severe hypercholesterolemia. Arteriosclerosis 1981; 1: 443-8
82. Nofer JR, Tepel M, Kehrel B, et al. Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia. Circulation 1997; 95: 1370-7
83. Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-7
84. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63
85. Rosenson RS, Tangney CC, Schaefer EJ. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis 2001; 155: 463-6
86. Wierzbicki AS, Lumb PJ, Semra YK, et al. Effect of atorvastatin on plasma fibrinogen. Lancet 1998; 351: 569-70
87. Avellone G, Di Garbo V, Cordova R, et al. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr Ther Res Clin Exp 1994; 55: 1335-44
88. Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14: 829-34
89. Blann AD, Gurney D, Hughes E, et al. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am J Cardiol 2001; 88; 89-92
90. Mitropoulos KA, Armitage JM, Collins R, et al. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. Eur Heart J 1997; 18: 235-41